Tevogen Bio Holdings Inc.
For the period ended Dec 31, 2025. Filed Mar 31, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 31, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized**.**
| Tevogen Bio Holdings Inc. | ||
| Date: March 31, 2026 | By: | /s/ Ryan Saadi |
|---|---|---|
| Ryan Saadi | ||
| Chief Executive Officer | ||
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant in the capacities and on the dates indicated.
| Signature | Date | Title |
|---|---|---|
| /s/ Ryan Saadi | March 31, 2026 | Chief Executive Officer and Chairperson of the Board of Directors |
| Ryan Saadi | (Principal Executive Officer) | |
| /s/ Kirti Desai | March 31, 2026 | Chief Financial Officer |
| Kirti Desai | (Principal Financial Officer and Principal Accounting Officer) | |
| /s/ Jeffrey Feike | March 31, 2026 | Director |
| Jeffrey Feike | ||
| /s/ Dr. Keow Lin Goh | March 31, 2026 | Director |
| Dr. Keow Lin Goh | ||
| /s/ Dr. Curtis Patton | March 31, 2026 | Director |
| Dr. Curtis Patton | ||
| /s/ Susan Podlogar | March 31, 2026 | Director |
| Susan Podlogar | ||
| /s/ Victor Sordillo | March 31, 2026 | Director |
| Victor Sordillo | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.